Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50

We previously reported that a single prostate‐specific antigen (PSA) measured at ages 44‐50 was highly predictive of subsequent prostate cancer diagnosis in an unscreened population. Here we report an additional 7 years of follow‐up. This provides replication using an independent data set and allows estimates of the association between early PSA and subsequent advanced cancer (clinical stage ≥T3 or metastases at diagnosis).

[1]  P. Scardino,et al.  Susceptibility Loci Associated with Prostate Cancer Progression and Mortality , 2010, Clinical Cancer Research.

[2]  Andrew J. Vickers,et al.  Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer , 2010, Cancer Prevention Research.

[3]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[4]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[5]  R. Eeles,et al.  SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design? , 2008, Nature genetics.

[6]  M. Thun,et al.  Variation in KLK genes, prostate-specific antigen and risk of prostate cancer , 2008, Nature Genetics.

[7]  R. Eeles,et al.  Reply to “Variation in KLK genes, prostate-specific antigen and risk of prostate cancer” , 2008, Nature Genetics.

[8]  Andrew J Vickers,et al.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden , 2008, BMC medicine.

[9]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[10]  Pär Stattin,et al.  Cumulative association of five genetic variants with prostate cancer. , 2008, The New England journal of medicine.

[11]  P. Scardino,et al.  Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Scardino,et al.  Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study , 2008, BMC medicine.

[13]  Andrew J Vickers,et al.  The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically‐based screening strategy , 2007, International journal of cancer.

[14]  M. Roobol,et al.  Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. , 2007, Journal of the National Cancer Institute.

[15]  M. Kattan,et al.  Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy , 2007, International journal of cancer.

[16]  Andrew J Vickers,et al.  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Holmberg,et al.  Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 , 2007, Scandinavian journal of urology and nephrology.

[18]  H. Lilja,et al.  Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein 2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(ab')(2) Fragments. , 2006 .

[19]  W. Catalona,et al.  Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. , 2006, Urology.

[20]  G. Berglund,et al.  Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. , 2006, Clinical chemistry.

[21]  H. Lilja,et al.  Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. , 2006, Analytical chemistry.

[22]  A. Whittemore,et al.  Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. , 2005, The Journal of urology.

[23]  P. Qiu.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2005 .

[24]  Dr. Andreas Böhle.  Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study , 2004 .

[25]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[26]  E. Varenhorst,et al.  Validity of a Population-Based Cancer Register in Sweden An Assessment of Data Reproducibility in the South-East Region Prostate Cancer Register , 2003, Scandinavian journal of urology and nephrology.

[27]  E. Metter,et al.  Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. , 2001, Urology.

[28]  Wen-Chung Lee,et al.  Probabilistic analysis of global performances of diagnostic tests: interpreting the Lorenz curve-based summary measures. , 1999, Statistics in medicine.

[29]  H. Lilja,et al.  Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. , 1995, Clinical chemistry.

[30]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[31]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[32]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .